🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  2. Placebo for PF-06651600-15, 50 mg, DEXAMETHASONE, Ritlecitinib tosilate, Placebo for PF-06651600-15, 100 mg, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    nonsegmental vitiligo

    phase 3 small molecule active

    1 trial

  3. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  4. Placebo for Ralinepag extended-release tablets, Ralinepag, Ralinepag, Ralinepag

    United Therapeutics Europe Ltd

    Pulmonary arterial hypertension (PAH)

    phase 3 small molecule active

    1 trial

  5. Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  6. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  7. Placebo for efgartigimod, ARGX-113

    argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  8. Placebo for efgartigimod, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  9. Placebo for empasiprubart- solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  10. Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant

    Astellas Pharma GmbH

    Moderate to Severe Vasomotor Symptoms (VMS)

    phase 3 small molecule active

    1 trial

  11. Placebo for glepaglutide, Glepaglutide 20.0 mg/mL

    Zealand Pharma A/S

    Short Bowel Syndrome

    phase 3 small molecule active

    1 trial

  12. Placebo for mepolizumab is a 0.9% sodium chloride solution in a syringe for subcutaneous injection., PREDNISOLONE, MEPOLIZUMAB, METHYLPREDNISOLONE, PREDNISONE, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    phase 3 small molecule active

    1 trial

  13. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  14. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  15. Placebo for risankizumab 300mg/3.33ml solution for infusion, ABBV-066 / Risankizumab, Placebo for Risankizumab 90mg/mL Solution for injection in Pre-filled Syringe, Risankizumab, ABBV-066, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  16. Placebo for risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  17. Placebo in combination with Cytarabine Injection

    Moleculin Biotech

    Acute Myeloid Leukaemia (AML)

    phase 3 small molecule active

    1 trial

  18. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  19. Placebo injections

    Centocor B.V.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  20. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  21. Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  22. Placebo is a solution for infusion of human albumin 1%, is an albumin preparation manufactured by dilution from the drug product of Albiomin 20%, it will be administrated via intravenous infusion., Trimodulin (human IgM, IgA, IgG solution)

    Biotest Pharma GmbH

    Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  23. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  24. Placebo is identical to the active NMRA-335140 but without the active drug substance to maintain study blinding., NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources